These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18941113)

  • 1. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
    Houot R; Levy R
    Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.
    Brody JD; Goldstein MJ; Czerwinski DK; Levy R
    Blood; 2009 Jan; 113(1):85-94. PubMed ID: 18812472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
    Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
    J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
    Marabelle A; Kohrt H; Sagiv-Barfi I; Ajami B; Axtell RC; Zhou G; Rajapaksa R; Green MR; Torchia J; Brody J; Luong R; Rosenblum MD; Steinman L; Levitsky HI; Tse V; Levy R
    J Clin Invest; 2013 Jun; 123(6):2447-63. PubMed ID: 23728179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
    Li J; Song W; Czerwinski DK; Varghese B; Uematsu S; Akira S; Krieg AM; Levy R
    J Immunol; 2007 Aug; 179(4):2493-500. PubMed ID: 17675511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.
    Varghese B; Widman A; Do J; Taidi B; Czerwinski DK; Timmerman J; Levy S; Levy R
    Blood; 2009 Nov; 114(20):4477-85. PubMed ID: 19762487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation Augments the Local Anti-Tumor Effect of
    Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
    Front Immunol; 2021; 12():763888. PubMed ID: 34868010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
    Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
    Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
    Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
    Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
    AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
    Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
    J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.
    Grille S; Brugnini A; Nese M; Corley E; Falkenberg FW; Lens D; Chabalgoity JA
    Cancer Immunol Immunother; 2010 Apr; 59(4):519-27. PubMed ID: 19768458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.